OptumRx in its latest drug pipeline update recommends payers to keep an eye on risdiplam, viltolarsen and trodelvy, FierceHealthcare reports.
OptumRx’s chief medical officer, Sumit Dutta, says orphan drugs could account for roughly 40 percent of approvals by the Food and Drug Administration this year.
“What is new is that we now are starting to see the development of orphan drugs become more competitive, increasing the potential for reduced costs and broader patient accessibility,” he says in the report.
To read FierceHealthcare’s full report, click here.
